Figure 1.
Patient outcome and disposition. Afib, atrial fibrillation; FCR, fludarabine, cyclophosphamide, and rituximab; IBR, ibrutinib, PD-CLL, progression of disease with chronic lymphocytic leukemia; Y, years.
Patient outcome and disposition. Afib, atrial fibrillation; FCR, fludarabine, cyclophosphamide, and rituximab; IBR, ibrutinib, PD-CLL, progression of disease with chronic lymphocytic leukemia; Y, years.
